Travere Therapeutics shares plunge as kidney-disease treatment has mixed results in trial
Summary by Ground News
2 Articles
2 Articles
All
Left
Center
2
Right
Why Is Kidney-Disease Focused Travere Therapeutics Stock Trading Lower Today? - Travere Therapeutics (NASDAQ:TVTX)
Travere Therapeutics Inc (NASDAQ: TVTX) announced topline two-year confirmatory secondary endpoint results from its head-to-head Phase 3 PROTECT Study of Filspari (sparsentan) in IgA nephropathy (IgAN) versus Sanofi SA's (NASDAQ: SNY) Avapro (irbesartan). Filspari demonstrated long-term kidney function preservation and achieved a clinically meaningful difference in estimated glomerular filtration rate (eGFR) total and chronic slope versus irbes…
·New York, United States
Read Full ArticleCoverage Details
Total News Sources2
Leaning Left0Leaning Right0Center2Last UpdatedBias Distribution100% Center
Bias Distribution
- 100% of the sources are Center
100% Center
C 100%
Factuality
To view factuality data please Upgrade to Premium
Ownership
To view ownership data please Upgrade to Vantage